Marie Thibault

Could you characterize the Core Lab trajectory by geography during Q1? Any share gains?

I wanted to get a little more detail on how to think about kind of the reach of those products

Can you catch us up to date on where we are in terms of the rollout

Can you just dive a little deeper into that? I know that, that's something you've been focused on for a couple of quarters

I wanted to understand what's going on in that product segment and understand how the Entera Oncology acquisition fits

I wanted to understand how sustainable some of that momentum feels to you out in the field, what you have seen since the quarter ended, and how much of it you think is linked to the 15-day launch v...

Would you have us thinking about any potential facing headwinds as we think about the Medicare unlock

It sounds like that had to do with materials around deployment. Is that to do with the inserter specifically? And as we think about it improving, is that something we can put in the rearview going ...

I wanted an update here then clinical trial work you guys have been doing. I believe that there was a trial underway

the OpEx control that's being sort of assumed in the guidance, especially with some of the impacts to gross margin

what you're seeing in the early Type 2 users retention the same as the type 1 users? Or is there any risk around that assumption